It's a token amount, but it signifies real, if tentative, interest from a major player in the regenerative med. market.
Firming up the IP estate around LEAP will strengthen these kinds of early negotiations, but it's important to remember this is extremely new (and for drug delivery), largely unproven tech. We're on the ground floor of what might be a revolution in medicine, or a tech that might fail to meet regulatory hurdles or the needs of big pharma. In this sense, EX1 is a super spec stock... which is reflected in the extremes of commentary on this thread.
In the end, it's about risk appetite and the risk/reward calculus. But it's also about timeframes for investment... and possibility. Which is why I'm in and, perhaps, why Showa Denko had to at least have a little look... GLTAH R-7
EX1 Price at posting:
51.0¢ Sentiment: None Disclosure: Held
